FMED - ETF AI Analysis
Top Page
Fidelity Disruptive Medicine ETF (FMED)
Rating:58Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong short-term results over the past month and quarter, suggesting positive momentum in its strategy.
Leading Innovative Health Care Holdings
Several top positions like 10x Genomics, Revolution Medicines, and Kymera Therapeutics have delivered strong year-to-date gains, supporting the fund’s returns.
Focused Exposure to Disruptive Medicine
With most assets in the health care sector and U.S. companies, the ETF offers targeted exposure to innovative medical and biotech firms.
Negative Factors
High Sector Concentration
The fund is heavily concentrated in health care, which increases risk if that sector faces regulatory or market challenges.
Mixed Performance Among Top Holdings
Some major holdings such as Danaher, Thermo Fisher, and Alnylam Pharma have shown weak year-to-date performance, which can drag on overall returns.
Above-Average Expense Ratio
The ETF’s fee is relatively high compared with many broad market funds, which slightly reduces the net return investors receive over time.
FMED vs. SPDR S&P 500 ETF (SPY)
AUM50.95M
RegionGlobal
Expense Ratio0.50%
Beta0.84
IssuerFidelity
Inception DateJun 12, 2023
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume5,766
30 Day Avg. Volume6,835
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
41.77Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering72
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FMED Summary
Fidelity Disruptive Medicine ETF (FMED) focuses on the theme of “disruptive medicine,” investing mainly in U.S. healthcare and biotech companies working on cutting-edge treatments, genetics, and medical technology. It does not track a traditional index, but instead follows this innovation-focused theme. Well-known holdings include Thermo Fisher Scientific and Danaher, along with firms in genomics and precision medicine. Someone might invest for long-term growth and diversification within the healthcare sector, especially if they believe medical innovation will expand over time. A key risk is that these specialized healthcare and biotech stocks can be very volatile and may go up and down more than the overall market.
How much will it cost me?The Fidelity Disruptive Medicine ETF (FMED) has an expense ratio of 0.50%, which means you’ll pay $5 per year for every $1,000 invested. This is higher than average because the fund is actively managed, focusing on innovative healthcare companies that require more research and expertise to select.
What would affect this ETF?The Fidelity Disruptive Medicine ETF (FMED) could benefit from ongoing advancements in biotechnology, genomics, and digital health, as well as increased global demand for innovative healthcare solutions. However, it may face challenges from regulatory changes, high research and development costs, and potential market volatility in the healthcare sector. Its global exposure and focus on disruptive medicine make it sensitive to both breakthroughs and setbacks in medical innovation.
FMED Top 10 Holdings
FMED is firmly planted in disruptive healthcare, with a global mix of biotech and medical technology names steering returns. High-flyers like Moderna, Natera, and 10x Genomics are doing most of the heavy lifting, as their stocks have been rising on strong momentum and optimism around next‑gen therapies and diagnostics. Illumina and Argenx are also pulling their weight, adding steady support. On the flip side, more traditional life-science tools players like Danaher and Sartorius Stedim are lagging a bit, acting as mild brakes on an otherwise innovation-fueled portfolio.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| 10x Genomics | 5.67% | $2.84M | $8.94B | 442.64% | 60 Neutral | |
| Thermo Fisher | 3.86% | $1.93M | $225.48B | 27.19% | 72 Outperform | |
| Natera | 3.65% | $1.83M | $47.41B | 95.20% | 73 Outperform | |
| Danaher | 3.60% | $1.80M | $140.70B | 5.31% | 75 Outperform | |
| Lifestance Health Group | 3.24% | $1.62M | $4.96B | 147.99% | 61 Neutral | |
| Argenx Se | 3.14% | $1.57M | $61.89B | 30.14% | 79 Outperform | |
| Revolution Medicines | 2.92% | $1.46M | $43.68B | 337.74% | 52 Neutral | |
| Illumina | 2.73% | $1.37M | $31.17B | 117.04% | 71 Outperform | |
| Sartorius Stedim Biotech | 2.51% | $1.25M | €18.19B | 10.45% | 61 Neutral | |
| Alnylam Pharma | 2.47% | $1.24M | $33.28B | -46.62% | 60 Neutral |
FMED Technical Analysis
Positive
―
Price Trends
30.23
Positive
27.88
Positive
27.11
Positive
Market Momentum
0.31
Positive
52.60
Neutral
28.49
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FMED, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 31.81, equal to the 50-day MA of 30.23, and equal to the 200-day MA of 27.11, indicating a neutral trend. The MACD of 0.31 indicates Positive momentum. The RSI at 52.60 is Neutral, neither overbought nor oversold. The STOCH value of 28.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FMED.
FMED Peer Comparison
Comparison Results
Performance Comparison
FMED
Fidelity Disruptive Medicine ETF
31.30
7.06
29.13%
MEDI
Harbor Health Care ETF
―
―
―
TMED
T. Rowe Price Health Care ETF
―
―
―
MEDX
Horizon Kinetics Medical ETF
―
―
―
BMED
Future Health ETF
―
―
―
JDOC
JPMorgan Healthcare Leaders ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents